A citation-based method for searching scientific literature

Aatur D Singhi, Ta-Chiang Liu, Justin L Roncaioli, Dengfeng Cao, Herbert J Zeh, Amer H Zureikat, Allan Tsung, J Wallis Marsh, Kenneth K Lee, Melissa E Hogg, Nathan Bahary, Randall E Brand, Kevin M McGrath, Adam Slivka, Kristi L Cressman, Kimberly Fuhrer, Roderick J O'Sullivan. Clin Cancer Res 2017
Times Cited: 96







List of co-cited articles
1026 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Yuchen Jiao, Chanjuan Shi, Barish H Edil, Roeland F de Wilde, David S Klimstra, Anirban Maitra, Richard D Schulick, Laura H Tang, Christopher L Wolfgang, Michael A Choti,[...]. Science 2011
70

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Ilaria Marinoni, Anja Schmitt Kurrer, Erik Vassella, Matthias Dettmer, Thomas Rudolph, Vanessa Banz, Fabio Hunger, Silvan Pasquinelli, Ernst-Jan Speel, Aurel Perren. Gastroenterology 2014
223
64

Whole-genome landscape of pancreatic neuroendocrine tumours.
Aldo Scarpa, David K Chang, Katia Nones, Vincenzo Corbo, Ann-Marie Patch, Peter Bailey, Rita T Lawlor, Amber L Johns, David K Miller, Andrea Mafficini,[...]. Nature 2017
371
54

Altered telomeres in tumors with ATRX and DAXX mutations.
Christopher M Heaphy, Roeland F de Wilde, Yuchen Jiao, Alison P Klein, Barish H Edil, Chanjuan Shi, Chetan Bettegowda, Fausto J Rodriguez, Charles G Eberhart, Sachidanand Hebbar,[...]. Science 2011
631
45

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Joo Young Kim, Jacqueline A Brosnan-Cashman, Soyeon An, Sung Joo Kim, Ki-Byung Song, Min-Sun Kim, Mi-Ju Kim, Dae Wook Hwang, Alan K Meeker, Eunsil Yu,[...]. Clin Cancer Res 2017
57
71

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C Yao, Manal Hassan, Alexandria Phan, Cecile Dagohoy, Colleen Leary, Jeannette E Mares, Eddie K Abdalla, Jason B Fleming, Jean-Nicolas Vauthey, Asif Rashid,[...]. J Clin Oncol 2008
26

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Shinichi Yachida, Efsevia Vakiani, Catherine M White, Yi Zhong, Tyler Saunders, Richard Morgan, Roeland F de Wilde, Anirban Maitra, Jessica Hicks, Angelo M Demarzo,[...]. Am J Surg Pathol 2012
276
25

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
Roeland F de Wilde, Christopher M Heaphy, Anirban Maitra, Alan K Meeker, Barish H Edil, Christopher L Wolfgang, Trevor A Ellison, Richard D Schulick, I Quintus Molenaar, Gerlof D Valk,[...]. Mod Pathol 2012
106
25

Everolimus for advanced pancreatic neuroendocrine tumors.
James C Yao, Manisha H Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M Wolin, Eric Van Cutsem, Timothy J Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G E de Vries,[...]. N Engl J Med 2011
23

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Arvind Dasari, Chan Shen, Daniel Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Tina Shih, James C Yao. JAMA Oncol 2017
971
22

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Christopher M Heaphy, Andrea P Subhawong, Seung-Mo Hong, Michael G Goggins, Elizabeth A Montgomery, Edward Gabrielson, George J Netto, Jonathan I Epstein, Tamara L Lotan, William H Westra,[...]. Am J Pathol 2011
287
20


DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Joo Kyung Park, Woo Hyun Paik, Kyoungbun Lee, Ji Kon Ryu, Sang Hyub Lee, Yong-Tae Kim. Oncotarget 2017
32
59

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond, Laetitia Dahan, Jean-Luc Raoul, Yung-Jue Bang, Ivan Borbath, Catherine Lombard-Bohas, Juan Valle, Peter Metrakos, Denis Smith, Aaron Vinik,[...]. N Engl J Med 2011
17

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Anguraj Sadanandam, Stephan Wullschleger, Costas A Lyssiotis, Carsten Grötzinger, Stefano Barbi, Samantha Bersani, Jan Körner, Ismael Wafy, Andrea Mafficini, Rita T Lawlor,[...]. Cancer Discov 2015
81
20

Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Antonio Pea, Jun Yu, Luigi Marchionni, Michael Noe, Claudio Luchini, Alessandra Pulvirenti, Roeland F de Wilde, Lodewijk A Brosens, Neda Rezaee, Ammar Javed,[...]. Ann Surg 2020
35
48

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
Christopher J VandenBussche, Derek B Allison, Mindy K Graham, Vivek Charu, Anne Marie Lennon, Christopher L Wolfgang, Ralph H Hruban, Christopher M Heaphy. Cancer Cytopathol 2017
25
64

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chang S Chan, Saurabh V Laddha, Peter W Lewis, Matthew S Koletsky, Kenneth Robzyk, Edaise Da Silva, Paula J Torres, Brian R Untch, Janet Li, Promita Bose,[...]. Nat Commun 2018
61
26

The genomic landscape of small intestine neuroendocrine tumors.
Michaela S Banck, Rahul Kanwar, Amit A Kulkarni, Ganesh K Boora, Franziska Metge, Benjamin R Kipp, Lizhi Zhang, Erik C Thorland, Kay T Minn, Ramesh Tentu,[...]. J Clin Invest 2013
172
15

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.
Edoardo Missiaglia, Irene Dalai, Stefano Barbi, Stefania Beghelli, Massimo Falconi, Marco della Peruta, Lorenzo Piemonti, Gabriele Capurso, Alessia Di Florio, Gianfranco delle Fave,[...]. J Clin Oncol 2010
371
15

The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Olca Basturk, Zhaohai Yang, Laura H Tang, Ralph H Hruban, Volkan Adsay, Chad M McCall, Alyssa M Krasinskas, Kee-Taek Jang, Wendy L Frankel, Serdar Balci,[...]. Am J Surg Pathol 2015
251
15

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
H Sorbye, S Welin, S W Langer, L W Vestermark, N Holt, P Osterlund, S Dueland, E Hofsli, M G Guren, K Ohrling,[...]. Ann Oncol 2013
462
15

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
M Falconi, B Eriksson, G Kaltsas, D K Bartsch, J Capdevila, M Caplin, B Kos-Kudla, D Kwekkeboom, G Rindi, G Klöppel,[...]. Neuroendocrinology 2016
500
15

Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Somak Roy, William A LaFramboise, Ta-Chiang Liu, Dengfeng Cao, Alyssa Luvison, Caitlyn Miller, Maureen A Lyons, Roderick J O'Sullivan, Amer H Zureikat, Melissa E Hogg,[...]. Gastroenterology 2018
32
46

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Paloma Cejas, Yotam Drier, Koen M A Dreijerink, Lodewijk A A Brosens, Vikram Deshpande, Charles B Epstein, Elfi B Conemans, Folkert H M Morsink, Mindy K Graham, Gerlof D Valk,[...]. Nat Med 2019
52
28

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Courtney A Lovejoy, Wendi Li, Steven Reisenweber, Supawat Thongthip, Joanne Bruno, Titia de Lange, Saurav De, John H J Petrini, Patricia A Sung, Maria Jasin,[...]. PLoS Genet 2012
347
14

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
14

Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.
Joshua M Francis, Adam Kiezun, Alex H Ramos, Stefano Serra, Chandra Sekhar Pedamallu, Zhi Rong Qian, Michaela S Banck, Rahul Kanwar, Amit A Kulkarni, Anna Karpathakis,[...]. Nat Genet 2013
185
13


Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.
Peter W Lewis, Simon J Elsaesser, Kyung-Min Noh, Sonja C Stadler, C David Allis. Proc Natl Acad Sci U S A 2010
493
13

Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.
Anna Karpathakis, Harpreet Dibra, Chistodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua Francis, Dahmane Oukrif, Dalvinder Mandair, Marinos Pericleous, Mullan Mohmaduvesh,[...]. Clin Cancer Res 2016
91
13

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall,[...]. N Engl J Med 2014
845
12

MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases.
Vincenzo Corbo, Irene Dalai, Maria Scardoni, Stefano Barbi, Stefania Beghelli, Samantha Bersani, Luca Albarello, Claudio Doglioni, Christina Schott, Paola Capelli,[...]. Endocr Relat Cancer 2010
93
11

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Laura H Tang, Brian R Untch, Diane L Reidy, Eileen O'Reilly, Deepti Dhall, Lily Jih, Olca Basturk, Peter J Allen, David S Klimstra. Clin Cancer Res 2016
150
11

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Angela Chou, Malinda Itchins, Philip R de Reuver, Jennifer Arena, Adele Clarkson, Amy Sheen, Loretta Sioson, Veronica Cheung, Aurel Perren, Christopher Nahm,[...]. Hum Pathol 2018
21
52

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker,[...]. J Clin Oncol 2009
10

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
Rachel Litman Flynn, Kelli E Cox, Maya Jeitany, Hiroaki Wakimoto, Alysia R Bryll, Neil J Ganem, Francesca Bersani, Jose R Pineda, Mario L Suvà, Cyril H Benes,[...]. Science 2015
249
10

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.
G Rindi, G Klöppel, H Alhman, M Caplin, A Couvelard, W W de Herder, B Erikssson, A Falchetti, M Falconi, P Komminoth,[...]. Virchows Arch 2006
10

Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.
Christodoulos P Pipinikas, Harpreet Dibra, Anna Karpathakis, Andrew Feber, Marco Novelli, Dahmane Oukrif, Guiseppe Fusai, Roberto Valente, Martyn Caplin, Tim Meyer,[...]. Endocr Relat Cancer 2015
29
34

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Jau-Yu Liau, Jen-Chieh Lee, Jia-Huei Tsai, Ching-Yao Yang, Tsung-Lin Liu, Zhi-Long Ke, Hung-Han Hsu, Yung-Ming Jeng. Mod Pathol 2015
38
26

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Michele Simbolo, Andrea Mafficini, Katarzyna O Sikora, Matteo Fassan, Stefano Barbi, Vincenzo Corbo, Luca Mastracci, Borislav Rusev, Federica Grillo, Caterina Vicentini,[...]. J Pathol 2017
98
10

Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Susumu Hijioka, Waki Hosoda, Keitaro Matsuo, Makoto Ueno, Masayuki Furukawa, Hideyuki Yoshitomi, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Shoji Nakamori,[...]. Clin Cancer Res 2017
74
13

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
David Clynes, Clare Jelinska, Barbara Xella, Helena Ayyub, Caroline Scott, Matthew Mitson, Stephen Taylor, Douglas R Higgs, Richard J Gibbons. Nat Commun 2015
133
10


Consensus guidelines for the management and treatment of neuroendocrine tumors.
Pamela L Kunz, Diane Reidy-Lagunes, Lowell B Anthony, Erin M Bertino, Kari Brendtro, Jennifer A Chan, Herbert Chen, Robert T Jensen, Michelle Kang Kim, David S Klimstra,[...]. Pancreas 2013
304
9

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
James C Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward Wolin, Jiri Tomasek, Markus Raderer, Harald Lahner, Maurizio Voi,[...]. Lancet 2016
549
9

The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Massimo Milione, Patrick Maisonneuve, Francesca Spada, Alessio Pellegrinelli, Paola Spaggiari, Luca Albarello, Eleonora Pisa, Massimo Barberis, Alessandro Vanoli, Roberto Buzzoni,[...]. Neuroendocrinology 2017
109
9

Distinct factors control histone variant H3.3 localization at specific genomic regions.
Aaron D Goldberg, Laura A Banaszynski, Kyung-Min Noh, Peter W Lewis, Simon J Elsaesser, Sonja Stadler, Scott Dewell, Martin Law, Xingyi Guo, Xuan Li,[...]. Cell 2010
788
9

Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1.
Yanan Cao, Zhibo Gao, Lin Li, Xiuli Jiang, Aijing Shan, Jie Cai, Ying Peng, Yanli Li, Xiaohua Jiang, Xuanlin Huang,[...]. Nat Commun 2013
81
11

MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior.
Claudia Roldo, Edoardo Missiaglia, John P Hagan, Massimo Falconi, Paola Capelli, Samantha Bersani, George Adrian Calin, Stefano Volinia, Chang-Gong Liu, Aldo Scarpa,[...]. J Clin Oncol 2006
600
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.